Price: $166.14
· 1 day: +14.30% · 5 days: +14.60% · 1 month: +16.85% · YTD: +17.97%
As of 2026-11-03 20:47 UTC.
52-week range: $122.14 – $186.12 (currently at 69% of the range).
NBIX is in an uptrend, momentum firm. $169.29 is the level overhead; $160.3 the first support below.
5 of 6 technical checks lean bullish.
| Trend | Uptrend · above 50-day & 200-day |
|---|---|
| Momentum | RSI 89.5 · neutral · MACD bullish |
| Trend strength | ADX 21.0 · developing |
| Location | +13.2% vs 50-day MA |
| 52-week range | -10% from high · +35% from low |
| Volatility | ATR 4.58 · ~2.8%/day |
| Level | Type | Distance |
|---|---|---|
| $169.29 (resistance) | swing zone | 1.9% |
| $175.0 (resistance) | round | 5.33% |
| $185.5 (resistance) | 52w high | 11.65% |
| $160.3 (support) | swing zone | -3.52% |
| $152.79 (support) | swing zone | -8.04% |
| $150.0 (support) | round | -9.71% |
| RSI (14) | 89.5 | MACD | 1.8743 |
|---|---|---|---|
| ADX (14) | 21.0 | ATR (14) | 4.58 |
| 50-day average | $146.75 | 200-day average | $147.61 |
Next earnings: 2026-11-02. NBIX earnings date, time and past reactions.
Report of 2026-11-03.
Neurocrine Biosciences (NBIX) jumped 12.8% on November 3, 2026, after a Q3 earnings beat that pushed revenue past $1.1 billion and lifted the stock above its 200-day average for the first time in months. The move flips the medium-term stance from bearish to bullish, but the reward-to-risk from here is not compelling. The balance of evidence leans positive over the next 2–6 weeks, yet conviction is only medium because the stock is overbought and the breakout math does not reach the 3-to-1 threshold that makes a trade worth the risk.
Neurocrine Biosciences reported Q3 2026 results on November 2, 2026, that beat expectations by a wide margin. Adjusted EPS came in at $3.29 versus the $1.91 consensus, and revenue of $1.12 billion topped forecasts by $80 million, according to Investing.com. The company also raised full-year INGREZZA sales guidance to $2.9–2.925 billion from $2.8 billion. This was not a marginal beat; it was a step-change in the growth narrative, with total revenue up 41% year-over-year and INGREZZA net sales reaching $801 million, up 17%, while CRENESSITY contributed $211 million and VYKAT XR added $107 million, per the PR Newswire release.
The market's reaction was immediate and sharp. The stock rose 12.8% in a single day, and over the past five days it is up 12.3%. That move is almost entirely stock-specific: the S&P 500 (SPY) fell 1.7% over the same period, and the healthcare sector ETF (XLV) rose 2.97%. NBIX outperformed its sector by 9.4 percentage points over five days, a clear sign that the earnings beat, not the tape, drove the rally. The stock had been lagging XLV by 7.4% over the past 50 days, so this is a catch-up move as much as a reaction to new information.
The debate now is whether this is the start of a sustained uptrend or a one-day spike. The bullish case is straightforward: the company is growing revenue at 41%, raised guidance, and management expects double-digit volume growth in 2027 to offset mid- to high single-digit net pricing headwinds, as reported by Seeking Alpha. The bearish case is that the stock is now priced for perfection. At $163.99, NBIX trades 20.5% below the mean analyst target of $206.22, but the low target is $150, and the stock is up 33.2% from its 52-week low of $123.10. The RSI is 88.87, deeply overbought, and volume on the breakout day was 78.3% below its 20-day average, suggesting the move may not have broad participation.
The earnings call, covered by Seeking Alpha, highlighted record profitability and a confident tone from management, but the 10-Q shows net income fell 1% to $206.5 million despite the revenue surge, indicating higher costs, per the SEC filing. That is a nuance the market is ignoring today, but it matters for the medium term.
The long-term trend has turned up. The stock is now above its 40-week average, and the daily trend runs with the weekly uptrend. The previous assessment, dated October 28, 2026, was bearish with high conviction, based on the price being below its 40-week average. That reading has changed. The stock reclaimed its 200-day average on November 3, and the structure now holds above $160.30, a swing zone. The thesis is intact and has strengthened, but the stock is in the early phase of a potential uptrend, not a mature one.
Over the next 2–6 weeks, the balance of evidence leans positive, but conviction is medium, with only 2 of 4 conviction points in favor. The daily trend aligns with the weekly uptrend, and the stock is leading the S&P 500 by 1.2% over 50 days. However, it still lags XLV by 7.4% over the same period, which is a caution flag. The strongest case against the bullish reading is the overbought condition: RSI at 88.87 and a 12.8% one-day spike suggest the stock may need to consolidate. The volume on the breakout day was 78.3% below its 20-day average, which undermines the conviction that this is a high-quality breakout. That is why conviction is not higher.
The structure holds above $160.30, a swing zone. A daily close below that level would be the first crack in the new uptrend, and a weekly close below $152.79 would end the trend. The 50-day average sits at $146.71, and the 200-day at $147.60, so the stock has room to fall before the trend is truly broken, but the immediate support is $160.30.
The upside breakout level is a daily close above $169.29, a swing zone, on volume above its 20-day average. From there, the first target is the 52-week high of $185.50. The stop would be $159.26, based on $160.30 minus a quarter of the ATR (4.18). That gives a reward-to-risk of 1.6 to 1, which does not meet the 3-to-1 threshold that makes a breakout worth the risk. To reach 3-to-1, the target would need to be higher or the stop tighter, but the next resistance after $185.50 is $200, which would change the math.
The picture would change on a weekly close below $152.79, a swing zone. That would negate the new uptrend and put the long-term trend back down. The one non-price fact that would change the picture is a negative update on INGREZZA's growth trajectory, such as a cut to 2027 guidance or a regulatory setback, which would undermine the core of the bull case.
Interactive NBIX chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs